Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.40, $0.15 better than the analyst estimate of $1.25. Revenue for the quarter came in at $478.5 million versus the consensus estimate of $474.59 million.

GUIDANCE:

Charles River Laboratories sees FY2018 EPS of $5.42-$5.57, versus the consensus of $5.58.

• Revenue growth, reported 7.2% - 8.2%

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.